Emmaus Life Sciences, Inc. engages in the discovery, development, marketing, and sale of treatments and therapies for rare and orphan diseases. The company is headquartered in Torrance, California and currently employs 34 full-time employees. The company went IPO on 2000-05-09. The firm is engaged in the discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. Its lead product, Endari (prescription grade L-glutamine oral powder) helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. The firm has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.